Experimental investigation of adipose-derived mesenchymal stem cell-derived exosomes in the treatment of osteoporosis via the hsa_circ_0028877/miR-4728-3p/PTCH1 axis.
Li J., Gu Q., Li Y., Gu Y., Chen Y., Wang L.
Animal Study, published in Int Immunopharmacol (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Int Immunopharmacol (2025)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41037850
- DOI
- 10.1016/j.intimp.2025.115625
Abstract (original English)
hsa_circ_0028877 may serve as a biomarker for postmenopausal osteoporosis (PMOP) based on bioinformatics analysis; nevertheless, the underlying mechanism remains ambiguous. ADSCs-derived exosomes (ADSCs-exos), as an innovative cell-free therapeutic agent that influences numerous biological processes, including immunological modulation, reduction of oxidative damage, and enhancement of tissue repair and regeneration. In vitro experiments were performed to evaluate the impact of hsa_circ_0028877 on cellular proliferation, osteogenic differentiation, and osteoclast differentiation. The study examined the regulatory function of ADSCs-exos on the hsa_circ_0028877/miR-4728-3p/PTCH1 axis and its therapeutic implications for osteoporosis. The ovariectomised rat (OVX) model was employed to simulate PMOP. The impact of hsa_circ_0028877 overexpression and knockdown on the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) were examined. The RNA immunoprecipitation (RIP) method was employed to validate the connection among hsa_circ_0028877, miR-4728-3p, and PTCH1. ADSCs-exos modulate their downstream molecular pathway by obstructing the nuclear transport of hsa_circ_0028877. The impact of ADSCs-exos on bone mass, trabecular microstructure, and the mineralization capacity of BMSCs was evaluated in a rat model. hsa_circ_0028877 is significantly expressed in ovariectomis
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.